Some 17 million Americans are living with genetic mutations tied to an increased risk of getting cancer, Cleveland Clinic ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

New research indicates that high levels of folate and vitamin B12 may elevate prostate cancer risk, particularly for ...

Men with prostate cancer that returns after surgery or radiation and are left with few options could benefit from a new ...

The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...

Men with suspected prostate cancer will be able to get a diagnosis on the NHS within a day, under “game-changing” new trials.

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS ...

Key Takeaways Combining enzalutamide with standard hormone therapy cut the risk of prostate cancer death by over 40% in a ...